The Contribution of Cardiac Fatty Acid Oxidation to Diabetic Cardiomyopathy Severity

Cells. 2021 Nov 21;10(11):3259. doi: 10.3390/cells10113259.

Abstract

Diabetes is a major risk factor for the development of cardiovascular disease via contributing and/or triggering significant cellular signaling and metabolic and structural alterations at the level of the heart and the whole body. The main cause of mortality and morbidity in diabetic patients is cardiovascular disease including diabetic cardiomyopathy. Therefore, understanding how diabetes increases the incidence of diabetic cardiomyopathy and how it mediates the major perturbations in cell signaling and energy metabolism should help in the development of therapeutics to prevent these perturbations. One of the significant metabolic alterations in diabetes is a marked increase in cardiac fatty acid oxidation rates and the domination of fatty acids as the major energy source in the heart. This increased reliance of the heart on fatty acids in the diabetic has a negative impact on cardiac function and structure through a number of mechanisms. It also has a detrimental effect on cardiac efficiency and worsens the energy status in diabetes, mainly through inhibiting cardiac glucose oxidation. Furthermore, accelerated cardiac fatty acid oxidation rates in diabetes also make the heart more vulnerable to ischemic injury. In this review, we discuss how cardiac energy metabolism is altered in diabetic cardiomyopathy and the impact of cardiac insulin resistance on the contribution of glucose and fatty acid to overall cardiac ATP production and cardiac efficiency. Furthermore, how diabetes influences the susceptibility of the myocardium to ischemia/reperfusion injury and the role of the changes in glucose and fatty acid oxidation in mediating these effects are also discussed.

Keywords: cardiac insulin resistance; diabetic cardiomyopathy; fatty acid oxidation; glucose oxidation; ischemia/reperfusion; lipotoxicity.

Publication types

  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Animals
  • Diabetic Cardiomyopathies / metabolism*
  • Diabetic Cardiomyopathies / pathology*
  • Fatty Acids / metabolism*
  • Humans
  • Models, Biological
  • Myocardium / metabolism*
  • Oxidation-Reduction
  • Severity of Illness Index*

Substances

  • Fatty Acids

Grants and funding